What to watch with CYP2C19 and blood sugar?

CYP2C19 is primarily a drug-metabolizing enzyme, known for processing medications like proton pump inhibitors (e.g., omeprazole), antidepressants (e.g., escitalopram), and clopidogrel. A direct link to blood sugar regulation is not well established. Indirectly, CYP2C19 variants could affect the efficacy or side effects of drugs that influence glucose metabolism (e.g., certain antidepressants that alter weight). Additionally, CYP2C19-dependent medications may alter gut microbiota, which in turn could affect blood sugar – but this is speculative. The evidence is weak and based on mechanistic reasoning, not robust clinical trials. For blood sugar control, lifestyle factors (diet, exercise) and established biomarkers (HbA1c, fasting glucose) are far more relevant. Genetic testing for CYP2C19 is not indicated for blood sugar management.